Managing New Treatments for Hepatitis C in Primary Care
|
|
- Ralph Hopkins
- 6 years ago
- Views:
Transcription
1 Managing New Treatments for Hepatitis C in Primary Care Christina Connel, PharmD, BCPS, AAHIVP Objectives 2 Review HCV disease burden Identify risk factors and recommended testing for HCV Describe who should be treated Describe monitoring before and during and after treatment Review direct acting HCV therapy options 1
2 HCV in the US Estimated 2.7 to 3.9 million people in the US 3 In 2014 Acute cases of acute HCV: 2,194 Estimated actual new cases: 30, 500 No. of deaths from HCV: 19,659 Liver disease was the 12 th leading cause of death Centers for Disease Control and Prevention (CDC, 2016) % 20-25% 1-4% risk/year Natural History of Hepatitis C. Assessed 8 April
3 5 HCV treatment cascade Yehia BR, Schranz AJ, Umscheid CA, Lo Re V III (2014) The Treatment Cascade for Chronic Hepatitis C Virus Infection in the United States: A Systematic Review and Meta-Analysis. PLOS ONE 9(7): e Guidelines can be found at 3
4 Risk factors 7 Injection-drug use (ever) Intranasal illicit drug use Percutaneous/parenteral exposures in an unregulated setting Long-term hemodialysis (ever) Healthcare workers after exposures to HCVinfected blood Children born to HCVinfected women Prior recipients of transfusions or organ transplants Persons who were ever incarcerated AASLD-IDSA HCV Guidance. HCV testing and linkage to care. Recommendations for testing and linkage to care. Date accessed here August 10, 2016 Screening 8 One time testing Patients born between 1945 and 1965 Patients with risk factors of HCV infection Patients behaviors or exposures associated with increased risk Annual testing IV drug users HIV-seropositive MSM Periodic testing should be offered to other persons with ongoing risk factors for exposure to HCV. AASLD-IDSA HCV Guidance. HCV testing and linkage to care. Recommendations for testing and linkage to care. Date accessed August 10,
5 CDC testing sequence Patients exposed in the last 6 months should receive follow up antibody testing or HCV RNA testing 9 Patients suspected to have had exposures in the last 6months or questions concerning the handling of the test specimen should have an RNA repeated AASLD-IDSA HCV Guidance. HCV testing and linkage to care. CDC Recommended Testing Sequence for Identifying Current HIV Infection. Date accessed January 16, 2017 Preventing Transmission 10 Avoid sharing toothbrushes/dental equipment or shaving equipment. Stop IVDU Avoid sharing/reusing needles Dispose of needles in a puncture-proof container Do not donate blood Avoid sexual transmission by using barrier protection in those Co-infection with HIV multiple sex partners Clean visible blood on household surfaces with bleach-water AASLD-IDSA HCV Guidance. HCV testing and linkage to care. Measures to prevent transmission of HCV. Date accessed January 16,
6 Treatment: Who? Why? When? 11 All patients should be treated except those with short life expectancies Goal of treatment is cure Reduces mortality and liver related disease Patient considerations Understanding Willingness to adhere/follow up Access to medication AASLD-IDSA HCV Guideance. HCV testing and linkage to care. When and in whom to initiate HCV therapy. Date accessed August 10, 2016 Pre-treatment Assessment Labs: Genotype/subtype Quantitative HCV RNA (HCV viral load) HBV status Resistance associated variants, when applicable 12 AASLD-IDSA HCV Guidance. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed August 25,
7 13 Child Pugh Score Encephalopathy None Grade 1-2 (or precipitant induced) Ascites None Mild/Moderate (diuretic-responsive) Grade 3-4 (or chronic) Severe (diuretic refractory) Bilirubin (mg/dl) <2 2-3 >3 Albumin (g/dl) > <2.8 PT or INR <4 < Bedosa P etal. Histologic and non invasive Estimates of Liver Fibrosis. Clinical Liver Disease. 2015; 6:5-8 Natural History of Hepatitis C. Assessed 8 April 2017 >6 >2.3 Pre-treatment labs 14 Within 12 weeks of starting treatment CBC and INR Hepatic function (ALT/AST; total and direct bilirubin, alkaline phosphatase) Renal function TSH (if interferon is used) AASLD-IDSA HCV Guidance. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed August 25,
8 Monitoring during treatment 15 Clinic visits or telephone contact as needed ensure medication adherence monitor for adverse events drug-drug interactions with newly prescribed medications. At week 4 of treatment CBC Renal and hepatic function HCV viral load Repeat 12 weeks after the end of treatment for SVR AASLD-IDSA HCV Guideance. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed August 25, 2016 Where we have come from. 16 Strader DB, Seeff LB. A Brief History of the Treatment of Viral Hepatitis C. Clinical Liver Disease. 2012;1(1):6-11. doi: /cld.a 8
9 Available HCV medications 17 Brand Generic Mechanism Olysio Simeprevir* NS3/4A Sovaldi Sofosbuvir* NS5B Harvoni Ledipasvir/sofosbuvir NS5A + NS5B Viekera Pak Viekera XR ombitasvir/paritaprevir/ritonavir and dasabuvir (PrOD) NS5A + NS3/4A + CYP3A + NS5B Technivie ombitasvir/paritaprevir/ritonavir NS3/4A + NS5A + CYP3A (PrO) Daklinza Daclatasvir* NS5A Zepatier Elbasvir/grazoprevir NS5A + NS3/4A Epclusa Sofosbuvir/velpatasvir NS5B + NS5A *must be used with an additional DAA 18 Treatment for Genotype 1a (naïve) Drug Duration Duration for compensated cirrhosis Simeprevir + sofosbuvir X 12 weeks X 24 weeks +/- ribavirin (alternative) Ledipasvir/sofosbuvir X 12 weeks X 12 weeks ombitasvir/paritaprevir/rito navir and dasabuvir (PrOD) + wt based ribavirin X 12 weeks X 24 weeks (alternative) Daclatasvir + sofosbuvir X 12 weeks X 24 weeks + ribavirin (alternative) Elbasvir/grazoprevir X 12 weeks* X 12 weeks* Sofosbuvir/velpatasvir X 12 weeks X 12 weeks * In whom no NS5A RAVs are detected AASLD-IDSA HCV Guidance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed August 10,
10 19 Treatment for Genotype 1b (naïve) Drug Duration Duration for compensated cirrhosis Simeprevir + sofosbuvir X 12 weeks X 24 weeks +/- ribavirin (alternative) Ledipasvir/sofosbuvir X 12 weeks X 12 weeks ombitasvir/paritaprevir/rito navir and dasabuvir (PrOD) X 12 weeks X 24 weeks Daclatasvir + sofosbuvir X 12 weeks X 24 weeks +/- ribavirin (alternative) Elbasvir/grazoprevir X 12 weeks X 12 weeks Sofosbuvir/velpatasvir X 12 weeks X 12 weeks AASLD-IDSA HCV Guideance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed here August 10, 2016 Treatment for Genotype 2 (naïve) 20 Drug Duration Duration for compensated cirrhosis Sofosbuvir/velpatasvir X 12 weeks X 12 weeks Daclatasvir + sofosbuvir X 12 weeks (alternative) X16-24 weeks (alternative) Treatment for Genotype 3 (naïve) Drug Duration Duration for compensated cirrhosis Sofosbuvir/velpatasvir X 12 weeks X 12 weeks Daclatasvir + sofosbuvir X 12 weeks 24 weeks AASLD-IDSA HCV Guidance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed here August 10,
11 Treatment for Genotype 4 (naïve) 21 Drug Duration Duration for compensated cirrhosis Ledipasvir/sofosbuvir X 12 weeks X 12 weeks ombitasvir/paritaprevir/ ritonavir (PrO) + wt based ribavirin Elbasvir/grazoprevir Sofosbuvir/velpatasvir X 12 weeks X 12 weeks X 12 weeks X 12 weeks X 12 weeks X 12 weeks Treatment for Genotype 5/6 (naïve) Drug Duration with or without compensated cirrhosis Ledipasvir/sofosbuvir X 12 weeks Sofosbuvir/velpatasvir X 12 weeks AASLD-IDSA HCV Guideance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed here August 10, 2016 Simeprevir + Sofosbuvir 22 Genotypes 1 a and b without cirrhosis Consider baseline polymorphism testing in cirrhotic patients Not recommended for those with Child-Pugh B or C Amiodarone AASLD-IDSA HCV Guideance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed here August 10, 2016 Olysio [package insert] Titusvill, NJ. Janssen Therapeutics
12 Simeprevir + Sofosbuvir 23 Administration Not coformulated Once daily with food Common ADRs Fatigue (16%), headache (17%), dizziness (3%), rash including photosensitivity (12%) Sulfa allergy? AASLD-IDSA HCV Guideance. HCV testing and linkage to care. Initial Treatment of HCV Infection. Date accessed here August 10, 2016 Olysio [package insert] Titusvill, NJ. Janssen Therapeutics Ledipasvir/sofosbuvir 24 Genotype 1, 4, 5, 6 With or without compensated cirrhosis Can we shorten to 8 weeks of therapy? Drug interactions Amiodarone Acid reducing agents Harvoni [package insert] Foster City, CA. Gildead Sciences Inc Lexicomp Online. 29 Aug
13 25 Ledipasvir/sofosbuvir Administration Coformulated Daily with or without food Common ADRs: >10% :headache, fatigue, weakness 5-10%Irritability, insomnia, dizziness, nausea, diarrhea, myalgia Harvoni [package insert] Foster City, CA. Gildead Sciences Inc Lexicomp Online. 29 Aug 2016 velpatasvir/sofosbuvir 26 Pan genotypic (1, 2, 3, 4, 5, 6) With or without compensated cirrhosis Common ADRs: >10%: Headache, fatigue 5-10%: Irritability, insomnia, nausea, weakness Drug interactions: Amiodarone Acid reducing agents Epclusa [package insert] Foster City, CA. Gildead Sciences Inc Lexicomp Online. 29 Aug
14 ombitasvir/paritaprevir/ritonavir and dasabuvir (PrOD) Available as an extended release product 27 Genotype 1 with or without cirrhosis + ribavirin in 1a patients ADRs (w/o ribavirin): (5-10%) nausea, pruritus and insomnia Drug interactions: multiple contains ritonavir Viekira XR [package insert] North Chicago, IL. AbbVie Inc Viekira Pak [package insert] North Chicago, IL. AbbVie Inc Lexicomp Online. 29 Aug 2016 ombitasvir/paritaprevir/ritonavir and dasabuvir (PrOD) Contraindicated in patients with Child Pugh class B or C 28 Increase risk of liver injury or progression to decompensated cirrhosis Usually within the first 4 weeks; associated with increase bilirubin and liver enzyme levels D/C Estrogen containing medications prior to use Viekira XR [package insert] North Chicago, IL. AbbVie Inc Viekira Pak [package insert] North Chicago, IL. AbbVie Inc Lexicomp Online. 29 Aug
15 ombitasvir/paritaprevir/ritonavir (PrO) Genotype 4 with or without cirrhosis + ribavirin ADRs (without ribavirin): (>10%) weakness, fatigue, nausea 29 Drug interactions: multiple contains ritonavir Contraindicated in patients with Child Pugh class B or C Same warnings as with PrOD Technivie [package insert] North Chicago, IL. AbbVie Inc Daclatasvir + sofosbuvir 30 Genotype 1 & 3 without cirrhosis Consider NS5A testing in cirrhotic patients ADRs: >10%: Headache, fatigue. 5-10%: Nausea, diarrhea Daklinza [package insert] Princeton, NJ. Brostol-Myers Squibb Company
16 Daclatasvir + sofosbuvir 31 Daclatasvir dosing: 60mg daily Strong CYP3A inhibitors: 30mg daily Moderate CYP3A inducers: 90mg daily Strong CYP3A inducers: contraindicated Amiodarone Daklinza [package insert] Princeton, NJ. Brostol-Myers Squibb Company Elbasvir/grazoprevir Genotype 1 & 4 with or without compensated cirrhosis 32 Requires baseline NS5A resistance testing Safe in patients with renal impairment Including those on HD Contraindicated in patients with Child Pugh class B or C Avoid use with moderate/strong CYP3A inducers ADRs: (>10%) Fatigue, headache, nausea Zepatier [package insert]whitehouse Station, NJ. Merck&Co, INC
17 Ribavirin 33 Weight based dosing Hemolytic Anemia Decrease dose if Hgb <10g/dL Discontinue if HgB<8.5g/dL Pregnancy Category X ADRs: GI effects, hematologic abnormalities, pruritus, rash, AASLD-IDSA. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed August 25, 2016 Lexicomp Online. 29 Aug 2016 Copegus [package insert] South Sanfancisco, CA. Genentech USA, INC When to stop treatment Safety A 10-fold increase in ALT at week 4 Any increase less than 10- fold at week 4 and accompanied with symptoms Asymptomatic less than 10- fold elevated at week 4 should be repeated at week 6 and week 8. Consideration discontinuation Efficacy Week 4 HCV RNA is detectable repeat viral load testing is at week 6. If viral load has increased by greater than 10-fold then discontinuation is recommended. The significance of positive a viral load that does not increase by 10-fold is unknown. 34 AASLD-IDSA. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed August 25,
18 Drug Interaction Resources 35 Monitoring after Treatment 36 For patients without advanced fibrosis (Metavir stage F0-F2: follow up as if never infected For patients with advanced fibrosis (Metavir stage F3-F4): Ultra sound every 6 months to screen for HCC Ongoing HCV monitoring is only recommended if patient has on going risk or otherwise explained hepatic dysfunction HCV RNA should be obtained rather than anti-hcv serology AASLD-IDSA. Monitoring patients who are starting Hepatitis C treatment, re on treatment, or have completed therapy. Date accessed 7 April
19 Summary 37 The largest drop in the treatment cascade is in diagnosis An estimated 50% of patients don t know they have HCV Treating HCV can decrease liver related mortality Treatment is now with direct acting agents Shorter duration Better tolerability HCV treatment is an every changing area of medicine Managing New Treatments for Hepatitis C in Primary Care Christina Connel, PharmD, BCPS, AAHIVP 19
Clinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationMonitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy
Monitoring Patients Who Are Starting HCV Treatment, Are On Treatment, Or Have Completed Therapy WV ECHO August 10, 2017 Selection of patients for HCV treatment Despite current guidance to treat everyone,
More informationHepatitis C Virus Management
Hepatitis C Virus Management FDA-Approved Medications Hepatitis C is caused by a virus and results in liver inflammation, which can lead to advanced liver disease and/or liver cancer. An estimated 3 to
More informationObjectives. Objectives. Introduction. Hepatitis A. Hepatitis B. At the end of the presentation, pharmacy technician participants will be able to:
Objectives A Revolution in Medicine: Advances in the Treatment of Hepatitis C Infection Spencer H. Durham, Pharm.D., BCPS (AQ ID) Assistant Clinical Professor of Pharmacy Practice Auburn University Harrison
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
PHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir ) Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir)
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy
New York State HCV Provider Webinar Series Side Effects of Therapy Objectives Understand the basics of HCV therapy Review the currently available regimens for treatment of HCV Appreciate side effects related
More informationPHARMACY PRIOR AUTHORIZATION Hepatitis C Clinical Guideline
Preferred Regimen Based on Diagnosis: Mavyret (glecaprevir/pibrentasvir) PHARMACY PRI AUTHIZATION Hepatitis C Clinical Guideline Non-Preferred: Daklinza (daclatasvir) Epclusa (sofosbuvir/velpatasvir) Harvoni
More informationPrimary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O.
Primary Care Approach to Diagnosis and Management of Chronic Hepatitis C Brian Viviano, D.O. Objectives Epidemiology of chronic hepatitis C CDC guidelines on screening or hepatitis C Diagnosing hepatitis
More informationCriteria for Indiana Medicaid Hepatitis C Agents
Prepared for State of Indiana by OptumRx EXECUTIVE SUMMARY Purpose: Promote prudent prescribing of Setting & Population: All members Type of Criteria: Increased Risk of ADE Non-Preferred Agent Appropriate
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES
HARVARD PILGRIM HEALTH CARE Generic Brand HICL GCN Exception/Other DACLATASVIR DAKLINZA 41377 ELBASVIR/GRAZOPREVIR ZEPATIER 43030 GLECAPREVIR/PIBRENTASVIR MAVYRET 44453 OMBITASVIR/PARITAPREVIR/ RITONAVIR
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationMolina Healthcare of Texas Hepatitis C Drugs (Medicaid)
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Hepatitis C Drugs (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o Patients who have prior exposure to DAA therapy
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.36 Subject: Daklinza Page: 1 of 8 Last Review Date: March 18, 2016 Daklinza Description Daklinza (daclatasvir)
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 7 Last Review Date: June 24, 2016 Daklinza Sovaldi Description Daklinza
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 20 Last Review Date: March 16, 2018 Hepatitis C Agents Description
More informationHepatitis C Agents
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.41 Subject: Hepatitis C Agents Page: 1 of 19 Last Review Date: December 8, 2017 Hepatitis C Agents
More informationNew York State HCV Provider Webinar Series. Side Effects of Therapy and Drug-Drug Interactions
New York State HCV Provider Webinar Series Side Effects of Therapy and Drug-Drug Interactions Case Presentation Case 56 year-old lady with Genotype 1A Hepatitis C, Treatment-naive Noninvasive fibrosis
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: July 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More informationHepatits C Criteria Direct Acting Antiviral Medications
Hepatits C Criteria Direct Acting Antiviral Medications Harvoni-Formulary PA required 1. Is the patient being treated for a funded condition by the Oregon Health Plan? 2. Does the member have a diagnosis
More informationRATIONALE FOR INCLUSION IN PA PROGRAM
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hepatitis C is a viral disease that causes inflammation of the liver that can lead to diminished liver function or liver failure. Most people infected with
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 30 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationProtocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)
PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and
More informationPegylated Interferon Agents for Hepatitis C
Applicable X X X X X X X Pegylated Interferon Agents for Hepatitis C Override(s) Prior Authorization Quantity Limit Initial for Monotherapy or Combination with Ribavirin based on Genotype, Status, or Co-Infection
More informationHepatitis C Virus (HCV)
Clinical Practice Guidelines Hepatitis C Virus (HCV) OBJECTIVE The purpose is to guide the appropriate diagnosis and management of Hepatitis C Virus (HCV). GUIDELINE These are only guidelines, and are
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1231-1 Program Prior Authorization/Notification Medication Mavyret (glecaprevir/pibrentasvir) P&T Approval Date 9/2017 Effective
More informationHepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18
Hepatitis C Infection: Updated Information for Front Line Workers in Primary Care Settings MAMTA K. JAIN, MD, MPH 2/14/18 Overview Hepatitis C Virus Prevalence Effects of Hepatitis C Prevention Diagnosis
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C Second Generation Antivirals Page 1 of 32 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C Second Generation Antivirals Through
More informationDaklinza Sovaldi. Daklinza (daclatasvir) and Sovaldi (sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Daklinza Sovaldi Page: 1 of 4 Last Review Date: September 18, 2015 Daklinza Sovaldi Description
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationVosevi (sofosbuvir/velpatasvir/voxilaprevir)
Vosevi (sofosbuvir/velpatasvir/voxilaprevir) Policy Number: 5.01.646 Last Review: 10/2017 Origination: 10/2017 Next Review: 11/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2132-1 Program Prior Authorization/Medical Necessity Medication Mavyret (glecaprevir/pibrentasvir) P&T Approval Date 9/2017 Effective
More informationClinical Policy: Glecaprevir/Pibrentasvir (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: Last Review Date: 06.18
Clinical Policy: (Mavyret) Reference Number: HIM.PA.SP36 Effective Date: 08.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Simeprevir (Olysio) Reference Number: CP.CPA.289 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Olysio) Reference Number: CP.CPA.289 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationHepatitis C Medications Hawaii PRIOR AUTHORIZATION REQUEST FORM
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: Last Review Date: 06.18
Clinical Policy: (Daklinza) Reference Number: HIM.PA.SP27 Effective Date: 01.01.17 Last Review Date: 06.18 Line of Business: HIM Revision Log See Important Reminder at the end of this policy for important
More informationUpdates in the Treatment of Hepatitis C
Disclosures Updates in the Treatment of Hepatitis C Arslan Kahloon M.D Assistant Professor of Medicine University of Tennessee, Chattanooga I have no conflicts of interest or financial sponsorship to disclose
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: December 2, 2016 Harvoni Description Harvoni (ledipasvir
More informationClinical Policy: Daclatasvir (Daklinza) Reference Number: CP.CPA.283 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Daklinza) Reference Number: CP.CPA.283 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Harvoni) Reference Number: CP.CPA.175 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationDescription of Antivirals for Hepatitis C. LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases
Description of Antivirals for Hepatitis C LCDR Dwayne David, PharmD, BCPS, NCPS Cherokee Nation Infectious Diseases Dwayne-David@cherokee.org Objectives Compare the different classes of direct-acting antiviral
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Epclusa) Reference Number: CP.CPA.286 Effective Date: 11.01.16 Last Review Date: 08.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More information1/16/2019. Goals of HCV Therapy. Objectives. Treating Hepatitis C and HIV Co Infection. Cure Defined as sustained virologic response (SVR)
HCV ECHO WESTERN STATES HCV ECHO WESTERN STATES Treating Hepatitis C and HIV Co Infection Paulina Deming, Pharm D Associate Professor, College of Pharmacy Assistant Director, Viral Hepatitis Programs,
More informationClinical Pharmacy Program Guidelines for Hepatitis C Agents ARIZONA. Preferred Agents: Mavyret (glecaprevir/pibrentasvir)
Clinical Pharmacy Program Guidelines for Hepatitis C Agents ARIZONA Program Medication Prior Authorization Hepatitis C Agents 1. State Mandated Criteria - LOD Preferred Agents: Mavyret (glecaprevir/pibrentasvir)
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.32 Subject: Harvoni Page: 1 of 9 Last Review Date: March 18, 2016 Harvoni Description Harvoni (ledipasvir
More informationPharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C
Pharmacy Medical Necessity Guidelines: Medications for the Treatment of Hepatitis C Effective: March 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationBrief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV)
Brief Review of HIV and Hepatitis C Virus (HCV) Infection (with focus on HCV) James Morrill, MD, PhD MGH Charlestown HealthCare Center Massachusetts General Hospital www.mghcme.org Disclosures Neither
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
DIRECT ACTING ANTIVIRAL AGENTS FOR HEPATITIS C VIRUS (HCV): DAKLINZA (daclatasvir) oral tablet EPCLUSA (velpatasvir, sofosbuvir) oral tablet HARVONI (ledipasvir, sofosbuvir) oral tablet MAVYRET (glecaprevir,
More informationHEPATITIS C. Whitney Dickson, PharmD, BCPS October 12 th, 2017
HEPATITIS C Whitney Dickson, PharmD, BCPS October 12 th, 2017 MY BACKGROUND Pharmacy School: University of California San Diego Pharmacy Practice Residency (PGY1): University of Illinois at Chicago HIV/Hep
More informationHepatitis C Genotype 1 (GT 1) Patients in the United States (US)
Hepatitis C Genotype 1 (GT 1) Patients in the United States (US) INDICATION is indicated with or without ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1, 4, 5, or
More informationAddress: City: State: ZIP code: Inferferon Product Requested (Include Strength):
Please complete this entire form and fax it to: 866-940-7328. If you have questions, please call 800-310-6826. This form contains multiple pages. Please complete all pages to avoid a delay in our decision.
More informationINFECTIOUS DISEASE AGENTS: HEPATITIS C - DIRECT - ACTING ANTIVIRAL
Ohio Department of Medicaid Prior Authorization Form Unified PDL HEPATITIS C TREATMENT Member ID# Patient Name: DOB: Patient Address: Provider DEA: Provider NPI: Provider Name: Phone: Provider Address:
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Technivie Page: 1 of 6 Last Review Date: March 18, 2016 Technivie Description Technivie (ombitasvir,
More informationPharmacy Medical Necessity Guidelines: Hepatitis C Virus
Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)
More informationPATIENT DETAIL Complete for each patient in the sample identified for review. Last Name: First Name: Middle Initial: Medical Record #
ehepqual Data Collection Tool This Data Collection Tool should be used to aid the extraction of data from each patient s medical record prior to manually entering the data into the ehepqual system. To
More informationDOB. More than one race or ethnicity Black non-hispanic American Indian/Alaska Native Hispanic. Native Hawaiian/Other Pacific Islander
ehepqual Data Collection Tool This Data Collection Tool should be used to aid the extraction of data from each patient s medical record prior to manually entering the data into the ehepqual system. To
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.03.32 Subject: Harvoni Page: 1 of 7 Last Review Date: December 3, 2015 Harvoni Description Harvoni (ledipasvir
More informationPart I. Prior Authorization Criteria and Policy
Texas Vendor Drug Program Antiviral Agents for Hepatitis C Virus Initial Authorization Request (Medicaid) Part I. Prior Authorization Criteria and Policy March 2018-E I. Eligibility 1. Patient is enrolled
More informationHCV Disease Outcomes in the US. Hepatitis C New Medications, New Hope and New Opportunities for Primary Care. Learning Objectives 10/13/17
Hepatitis C New Medications, New Hope and New Opportunities for Primary Care Disclosures: Grant for quality improvement Gilead In this talk, 10 drugs will be discussed, 4 of which are manufactured by Gilead.
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 July August
BRAND NAME Technivie GENERIC NAME Ombitasvir/paritaprevir/ritonavir MANUFACTURER AbbVie, Inc. DATE OF APPROVAL February 27, 2017 PRODUCT LAUNCH DATE Already available on the market REVIEW TYPE Review type
More informationSOFOSBUVIR/VELPATASVIR Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR
Generic Brand HICL GCN Exception/Other SOFOSBUVIR/ VELPATASVIR EPCLUSA 43561 GUIDELINES FOR USE 1. Is the patient at least 18 years old? If yes, continue to #2. 2. Does the patient have a diagnosis of
More informationHepatitis C Update: A Growing Challenge With Evolving Management Solutions
Pts (%) Hepatitis C Update: A Growing Challenge With Evolving Management Solutions A Growing Challenge With Evolving Management Solutions Introduction Magda Houlberg, MD Chief Clinical Officer Howard Brown
More informationSovaldi (sofosbuvir)
Market DC Sovaldi (sofosbuvir) Override(s) Prior Authorization Quantity Limit Approval Duration Based on Genotype, Treatment status, Cirrhosis status, or Ribavirin Eligibility status **IN, SC, WA Medicaid
More informationHarvoni. Harvoni (ledipasvir & sofosbuvir) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Harvoni Page: 1 of 7 Last Review Date: June 19, 2015 Harvoni Description Harvoni (ledipasvir &
More informationSASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary
April 1, 2017 Bulletin #165 ISSN 1923-0761 SASKATCHEWAN FORMULARY BULLETIN Update to the 62nd Edition of the Saskatchewan Formulary Related Information for Prescribers: Only prescribers who have completed
More informationHepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity. Cody A. Chastain, MD
Hepatitis C in Correctional Facilities: Big Problem, Bigger Opportunity Cody A. Chastain, MD Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Diagnosis Clinical Criteria for Hepatitis C (HCV) Therapy Must have chronic hepatitis C (HCV infection > 6 months), genotype and sub-genotype specified to determine the length of therapy; Liver biopsy
More informationLength of Authorization: 8-12 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationREQUEST FOR PRIOR AUTHORIZATION Hepatitis C Treatments
Fax completed form to: 866-940-7328 Prior Authorization Phone Number: 800-310-6826 IA Medicaid Member ID # Patient name Date of Birth Patient address Patient phone Provider NPI Prescriber name Phone Prescriber
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationState of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT
State of Maine Department of Health & Human Services MaineCare/MEDEL Prior Authorization Form HEPATITIS C TREATMENT HCV Phone: 1-888-445-0497 www.mainecarepdl.org Fax: 1-888-879-6938 Member ID #: Patient
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationUpdates in the Treatment of HCV
Updates in the Treatment of HCV Misty Miller, Pharm.D., BCPS, AAHIVP Associate Professor University of Oklahoma College of Pharmacy September 21 st, 2018 Overview HCV Review and Definitions HCV Genotypes
More informationSovaldi (sofosbuvir) with PegIntron (peginterferon alfa-2b) and Ribavirin (Copegus, Moderiba, Rebetol, RibaPak, Ribasphere, RibaTab, ribavirin)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.24 Subject: Sovaldi PegIntron Ribavirin Page: 1 of 6 Last Review Date: November 30, 2018 Sovaldi PegIntron
More informationTreatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy
Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationDrug Class Prior Authorization Criteria Hepatitis C
Drug Class Prior Authorization Criteria Hepatitis C Line of Business: Medicaid P & T Approval Date: November 14, 2018 Effective Date: January 1, 2019 This drug class prior authorization criteria have been
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationTreatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie )
Treatment of Hepatitis C with ombitasvir, paritaprevir, and ritonavir (Technivie ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO
More informationHepatitis C (Hep C) By Joshua Rollins. Transmission/Reservoirs
Hepatitis C (Hep C) By Joshua Rollins Etiological Agent: Hepatitis C virus (HCV) Transmission/Reservoirs Reservoir: Human The infection stems from the Hepatitis C virus (HCV), which is Blood borne pathogen
More informationHepatitis C Update on New Treatments
Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationIt is the policy of health plans affiliated with Centene Corporation that Mavyret is medically necessary when the following criteria are met:
Clinical Policy: (Mavyret) Reference Number: CP.CPA.285 Effective Date: 08.15.17 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationZepatier is contraindicated in patients with moderate to severe hepatic impairment (Child-Pugh B or C) due to potential toxicity (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Zepatier Page: 1 of 6 Last Review Date: June 24, 2016 Zepatier Description Zepatier (elbasvir,
More informationTechnivie. Technivie (ombitasvir, paritaprevir, ritonavir) and Ribavirin. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.37 Subject: Technivie Page: 1 of 6 Last Review Date: December 8, 2017 Technivie Description Technivie
More informationOptimizing HCV Treatment Continuity and Outcomes
Optimizing HCV Treatment Continuity and Outcomes Empowering Pharmacists to Take Action Faculty Michelle T. Martin, PharmD, BCPS, BCACP Clinical Pharmacist University of Illinois Hospital and Health Sciences
More informationHepatitis C Medications Prior Authorization Criteria
Hepatitis C Medications Authorization Criteria Epclusa (/velpatasvir), Harvoni (ledipasvir/), Sovaldi (), Daklinza (daclatasvir), Zepatier (elbasvir/grazoprevir), Olysio (simeprevir), Viekira Pak (ombitasvir/paritaprevir/ritonavir;
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2052-10 Program Prior Authorization/Medical Necessity Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 4/2015, 8/2015,
More informationOutpatient Pharmacy Effective Date: August 15, 2014
Therapeutic Class Code: W5Y, W5V, W0B, W0D, W0A, W0E Therapeutic Class Description: Hepatitis C Virus nucleotide analog NS5B RNA Dependent Polymerase Inhibitor, Hepatitis C Virus NS3/4A Serine Protease
More informationHepatitis C Update: Screening, Diagnosis, and Treatment
Mountain West AIDS Education and Training Center Hepatitis C Update: Screening, Diagnosis, and Treatment Brian R. Wood, MD (bwood2@uw.edu) Assistant Professor of Medicine, University of Washington Medical
More information